Navigation Links
Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
Date:8/5/2009

SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today reported financial results for the second quarter ended June 30, 2009. Optimer reported a net loss for the second quarter of 2009 of $12.4 million, or $0.37 per share, which was in line with the Company's expectations. This compares to a net loss for the second quarter of 2008 of $8.1 million, or $0.29 per share. The increase in net loss was primarily due to higher research and development expenses. Research and development expenses in the second quarter of 2009 were $10.5 million, compared to $6.2 million in the second quarter of 2008. The increase was primarily due to manufacturing scale-up expenses and expenses to prepare regulatory filings related to the Company's fidaxomicin and prulifloxacin programs.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

As of June 30, 2009, Optimer held cash, cash equivalents and short-term investments of $51.2 million.

"During the second quarter, we had the first oral presentations of our North American Phase 3 fidaxomicin data at major scientific conferences showing that fidaxomicin is more effective than oral vancomycin when it comes to reducing recurrence of CDI, even in high risk patient populations," said Michael N. Chang, Ph.D., Optimer's President and Chief Executive Officer. "As we head into the second half of this year, we look forward to presenting additional data from this study at ICAAC and IDSA and we are focused on completing our second fidaxomicin Phase 3 trial and preparing regulatory filings for fidaxomicin and prulifloxacin."

Recent Corporate Highlights

  • Clinical inves
    '/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
2. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
3. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
4. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
5. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
6. Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
8. Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
9. Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level
10. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
11. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... GLASGOW, Scotland , September 17, 2014 ... a new mode of action from a ... a decade  MGB Biopharma, a ... of anti-infectives, announces today that it has ... of its lead antibacterial, MGB-BP-3, against a ...
(Date:9/16/2014)... Washington, USA (PRWEB) September 16, 2014 ... to create the features that we desire in optical ... Center at Montana State University. “As we explore surfaces ... Some of those lessons were presented in San Diego ... of Light: Light in Nature ” chaired by Shaw ...
(Date:9/16/2014)... 16, 2014 --The emerging field of molecular electronics ... next level, enabling the construction of tiny circuits ... individual molecules would take on the roles currently ... A team of researchers from five Japanese and ... use in small-scale electronics: a molecule called picene. ...
(Date:9/16/2014)... HILL, N.C. , Sept. 16, 2014 ... experimental heart failure compound has been shown to be ... preclinical results demonstrate an alternative to intravenous infusions that ... HNO prodrugs. The data were presented yesterday at the ... Annual Scientific Meeting in Las Vegas ...
Breaking Biology Technology:MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5The future face of molecular electronics 2Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2
... DIEGO, April 15 Mr. Glynn has over 34 ... is well,known within the life sciences industry for his ... Most notably, Mr. Glynn,retired from Invitrogen Corporation (Nasdaq: ... company, he held several operating roles including CFO,President and ...
... NEW HAVEN, Conn., April 15 Vion,Pharmaceuticals, Inc. (Nasdaq: ... a,plan to achieve and sustain compliance with The Nasdaq ... of the plan., Previously, the Company announced that ... The Nasdaq Stock Market, Inc., notifying the Company,that it ...
... April 15 SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) ... the,American Association for Cancer Research (AACR) in San Diego. ... of the HGF,receptor tyrosine kinase (MET), inhibits growth of ... the afternoon poster session,entitled Small Molecule Kinase Inhibitors 1 ...
Cached Biology Technology:eBioscience Corporation Announced Today That James Glynn Has Been Appointed to Its Board of Directors, Effective April 15, 2008 2Vion Pharmaceuticals Files Plan With Nasdaq 2Vion Pharmaceuticals Files Plan With Nasdaq 3SGX Presents Preclinical MET Data at AACR 2SGX Presents Preclinical MET Data at AACR 3
(Date:9/17/2014)... Trees have been growing significantly faster since the 1960s. ... barely changed, but they have accelerated -- by as ... a study carried out by scientists from Technische Universitt ... that have been continuously observed since 1870. Their findings ... Three decades ago, "forest dieback" was a hot topic, ...
(Date:9/16/2014)... women in Australia is increased by lower socioeconomic ... September) in BJOG: An International Journal of ... high standards of living; however, existing research has ... indigenous and non indigenous Australians. , This case-control ... socioeconomic position on severe maternal morbidities associated with ...
(Date:9/16/2014)... taught us that we inherit certain traits from our ... change how these genes play out by taking certain ... That,s exactly what a team of researchers at the ... their research of epigenetics research. , Epigenetics regulates ... DNA and histone proteins, which prevent permanent mutations or ...
Breaking Biology News(10 mins):Global change: Trees continue to grow at a faster rate 2Global change: Trees continue to grow at a faster rate 3New study examines the impact of socioeconomic position & maternal morbidity in Australia 2New study examines the impact of socioeconomic position & maternal morbidity in Australia 3Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3
... MCLEAN, Va., Nov. 29, 2012  Northrop Grumman Corporation (NYSE: ... proof of concept for an automated biometric information system ... will be operated for a trial period to enable ... enabled intelligence and to help determine the requirements for ...
... William Cooke, a professor in the UTSA College of Education ... selected to serve as the speaker of the Texas Chapter ... Tour. Over the course of a week, Cooke will deliver ... of ACSM,s Texas Chapter. "This is a big honor ...
... For the first time in its history, the American Society ... opening session of the ASCB,s Annual Meeting, for "An Evening ... Francisco, on Saturday, Dec. 15. Members of the ... will receive complimentary registration to the ASCB keynote addresses ...
Cached Biology News:Northrop Grumman Delivers Australian Automated Biometric Information System Trial Proof of Concept 2UTSA physiologist William Cooke named 2013 Lecture Series Speaker by Texas Sports Medicine Chapter 2Public invited to 'An Evening of Science & Art' at ASCB Annual Meeting 2
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
SHEEP ANTI FLECAINIDE...
ANTI PIG LDH H4...
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
Biology Products: